PAXLOVID™ (Nirmatrelvir 150mg/Ritonavir 100mg) Access Form – Inpatient initiation

Southern Health and Social Care Trust
Quality Care - for you, with you

Write in CAPITAL LETTERS or use addressograph

Surname:_____

First names:_____

Health and Care No:_____

DOB:_____

Ward/Department:_____

Weight:_____ **eGFR:**_____

Allergies / Medicine sensitivities
This section must be completed before prescribing and administration except in exceptional circumstances

Date of Reaction	Medicine/allergen	Type of reaction (eg. rash)	Signature/ designation/date

Or

☐ No known allergies (Please tick)

Signature / Designation: Date:

Inclusion Criteria (ALL MUST APPLY)	**Indicate Yes or No**
SARS-CoV-2 infection is confirmed by either PCR testing or lateral flow test	
Treatment commenced within **FIVE** days of symptom onset	
Have an increased risk of progression to severe COVID-19 as per section 5 of NICE technology appraisal. State risk group: _____ ☐ Aged 85 years or over ☐ **Resident in a care home, or are already hospitalised and:** Age 70 years Or BMI of 35 kg/m^2 or more Or Diabetes Or Heart failure ☐ State risk group: _____ People on the organ transplant waiting list ☐ People with end-stage heart failure who have a long-term ventricular assistance device ☐	**At least one of the risk factors listed must apply however more than one may be applicable** **Please tick**
Exclusion Criteria (Patients are **NOT** eligible if they meet any of the following)	**Indicate Yes or No**
Severe COVID-19 infection **If a patient requires hospitalisation due to severe or critical COVID-19 after starting treatment with Paxlovid, the patient should complete the full 5-day treatment course at the discretion of their healthcare provider.	
New supplemental oxygen requirement specifically for the management of COVID-19 symptoms	
Known hypersensitivity reaction to the active substances or to any of the excipients of the products as listed in the Summary of Product Characteristics (SmPC)	
Age less than 18 years	
Renal failure or severe renal impairment (eGFR <30mL/min)	
Severe (Child-Pugh Class C) hepatic impairment	
Patient taking any medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions	
Patient taking any medicinal products that are potent CYP3A inducers	

INFORMATION REGARDING DRUG INTERACTIONS ACTIONED AND SIGNED BELOW

Due to recent marketing authorisation of Paxlovid™, information regarding significant drug interactions will continue to be updated as further data becomes available. **It is the responsibility of the prescribing clinician to review the patient's medications, both prescribed and non-prescribed and screen for interactions:** The following interaction checker is a useful resource Liverpool COVID-19 Interactions (covid19-druginteractions.org).

Patient's medications have been reviewed including NIECR (please tick box and sign) ☐ Signature: _____

There is a funding variation in place for nirmatrelvir plus ritonavir until 1 June 2025. See NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab.

SHSCT Pharmacy Department Version 3.0

Reference: NICE Technology Appraisal 878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. Published: 29 March 2023; Last updated: 13 March 2024
NICE guideline 191: COVD-19 rapid guideline: managing COVID-19 Published: 23 March 2021, Last updated: 8 May 2024
SPC Paxlovid 150 mg/100 mg film-coated tablets Last updated on emc: 16 Jan 2024
UK Paxlovid Highest Risk Cohorts One Pager NICE Eligibility Expansion June 2024

PAXLOVID™ (Nirmatrelvir 150mg/Ritonavir 100mg)

Southern Health and Social Care Trust
Quality Care - for you, with you

Access Form – Inpatient initiation

Drug	eGFR (ml/min/1.73m$^{2)}$	Dose and Frequency	Duration	Tick required dose
Paxlovid™ Nirmatrelvir/ Ritonavir	≥60	Nirmatrelvir 300mg PO BD **Plus** Ritonavir 100mg PO BD	5 days	
	30-59	Nirmatrelvir 150mg PO BD **Plus** Ritonavir 100mg PO BD	5 days	

Prescriber's Signature:_____ Prescriber's Name:_____

Grade: _____ GMC_____ Contact No:_____

Date:

Pharmacy Section:
Scanned copies to be sent to pharmacy, after clinical check on ward. If not clinically checked on ward, original must be sent to Pharmacy Department.
For patients receiving a reduced dose, remove one morning and evening dose of Nirmatrelvir when dispensing.

CC		LAB		DISP		FC		DATE	

Prescribe Paxlovid™ on kardex as per example below-

(a)



(b)



Fig 1: Prescription of Paxlovid on Acute Adult Medicine Kardex for (a) patients with normal renal function and (b) patients with an eGFR 30-59ml/min

Reference: NICE Technology Appraisal 878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. Published: 29 March 2023; Last updated: 13 March 2024
NICE guideline 191: COVD-19 rapid guideline: managing COVID-19 Published: 23 March 2021, Last updated: 8 May 2024
SPC Paxlovid 150 mg/100 mg film-coated tablets Last updated on emc: 16 Jan 2024
UK Paxlovid Highest Risk Cohorts One Pager NICE Eligibility Expansion June 2024

PAXLOVID™ (Nirmatrelvir 150mg/Ritonavir 100mg)

Counselling Checklist

Advice to be given to the patient by the prescribe in addition to patient information leaflet :	**Please Tick**
• The most common adverse reactions reported during treatment with Paxlovid™ were altered taste (Dysgeusia), diarrhoea, nausea and headache. • To reduce the possibility of emerging resistance, patients should be advised to complete the whole course of treatment even if their symptoms improve and/or they feel better. Any unused drug should be returned to the local community pharmacy. • A missed dose should be taken as soon as possible and within 8 hours of the scheduled time, and the normal dosing schedule resumed thereafter. If a dose is missed by more than 8 hours, the missed dose should not be taken and instead the next dose should be taken at the regularly scheduled time. • There are limited data from the use of Paxlovid™ in pregnant women. Paxlovid™ should be used during pregnancy only if the potential benefits outweigh the potential risk for the mother and the foetus. • As use of ritonavir may reduce the efficacy of combined hormonal contraceptives, patients using combined hormonal contraceptives should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during treatment and until after one complete menstrual cycle after stopping Paxlovid™. • In breast-feeding mothers, risks to the newborn/infant cannot be excluded therefore breast-feeding should be discontinued during treatment with Paxlovid™ and for 7 days after the last dose of Paxlovid™. **Signed:**_____ **Print Name:**_____ **Job Title:** _____ **Date:** _____	

Reference: NICE Technology Appraisal 878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. Published: 29 March 2023; Last updated: 13 March 2024
NICE guideline 191: COVD-19 rapid guideline: managing COVID-19 Published: 23 March 2021, Last updated: 8 May 2024
SPC Paxlovid 150 mg/100 mg film-coated tablets Last updated on emc: 16 Jan 2024
UK Paxlovid Highest Risk Cohorts One Pager NICE Eligibility Expansion June 2024